en
Scientific article
English

Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis

Published inJournal of clinical pathology, vol. 60, no. 6, p. 709-714
Publication date2007
Abstract

BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored. Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections. RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder. CONCLUSION: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.

Citation (ISO format)
MHAWECH-FAUCEGLIA, Paulette et al. Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. In: Journal of clinical pathology, 2007, vol. 60, n° 6, p. 709–714. doi: 10.1136/jcp.2006.039917
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0021-9746
493views
0downloads

Technical informations

Creation05/28/2013 3:43:27 PM
First validation05/28/2013 3:43:27 PM
Update time03/14/2023 8:30:19 PM
Status update03/14/2023 8:30:18 PM
Last indexation02/12/2024 8:29:58 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack